|Day Low/High||64.21 / 65.02|
|52 Wk Low/High||45.45 / 68.12|
Acquiring Medivation will strengthen Pfizer's oncology franchise, which has lost ground in recent years to some Big Pharma competitors.
A recent note from RBC Capital on Gilead gained a lot of attention as well as a pickup in call-option purchases.
RBC Capital analysts say this would free 'trapped value' on drug treatments.
Small biotech tanked on weak earnings, but still seems promising.
RBC Capital analysts say splitting the company into two distinct businesses would free 'trapped value' on drug treatments.
A review of earnings for portfolio names, along with upcoming dividend reminders.
Stocks retreat from record highs on Monday as a selloff in health care overshadows a rally in energy.
Stocks pull slightly lower on Monday as a selloff in health care squares off against a rally in energy.
Stocks pull lower on Monday morning as a selloff in health care sours the jobs-inspired rally that pushed benchmark indices to record highs last week.
Stocks secure robust gains after the latest labor market snapshot breezes past expectations.
AbbVie is suing Amgen in an attempt to block the rival biopharmaceutical company from producing a copycat of its Humira drug.
Rarely do investors get to buy these types of quality businesses at such discounted prices.
Cramer wants you to stick with Abbvie and says Cepheid is working.
Cramer has seen enough in this earnings season to come to some conclusions on what's working and what isn't.
The beaten-down biotech sector is making an impressive comeback. The sector seems to be rebounding after tumbling by more than 40%.
The sector seems to be rebounding after tumbling by more than 40%.
AbbVie is setting up well for a run back up to its 2015 highs.
The bifurcation can be seen just by looking at Apple's recent results.
In the last year, shares of Gilead Sciences are down 32%. With competition increasing for its hepatitis-C treatment, it is unlikely shareholders will see any relief.
The S&P 500 ends a record-making July with only slight gains on Friday.
Shares of AbbVie were up Friday after the company reported a big jump in revenue.
Consider raising your sell stop protection to a close below $61.
The S&P 500 moves higher on Friday, on track to end the month on a high, as Alphabet and Amazon rally on positive earnings.
The Anheuser-Busch InBev and SABMiller deal is another step closer to completion.
The company reported better-than-expected earnings and revenue Friday.
Stocks fluctuate on Friday morning as the mix of earnings reports again pulls Wall Street in two directions.
Stock futures are mixed on Friday morning after second-quarter economic growth in the U.S. falls short of economists' expectations.